Page 109 - MemoriaEHD-Eng

www.ciberehd.org

• B C, L MC, M r, M tM, a Jg, L JJ. Prospective mul-
Most relevant eNítezoNDoñoiQueLaNziaBraLDesozaNo
ticenter clinical trial of immunosuppressive drug withdrawal in stable adult liver
scientific transplant recipients.Hepatology. 2013 Nov;58(5):1824-35.

articles
• Mariño z, Crespo g, D’aMato M, BraMBiLLa N, giaCoveLLi g, rovati L. Intravenous silibinin
monotherapy shows significant antiviral activity in HCV-infected patients in the peri-

transplantation period.J Hepatol. 2013 Mar;58(3):415-20.

• peraLta C, JiMéNez-Castro MB, graCia-saNCho J. Hepatic ischemia and reperfusion in-
jury: effects on the liver sinusoidal milieu. J Hepatol. 2013 Nov;59(5):1094-106.

• s-C s, F C, C D, F J, t p, F J. Importance of
áNChezaBÚsoNDeviLaaLatayuDerrerauráuster
the temporary portocaval shunt during adult living donor liver transplantation.Liver
Transpl. 2013 Feb;19(2):174-83.

• C g, C Ja, C-L M, M z, L s, p-D-p s. Combina-
respoarrióNotoLereNaariñoeNsérezeLuLgar
tions of simple baseline variables accurately predict sustained virological response in
patients with recurrent hepatitis C after liver transplantation.J Gastroenterol. 2013

Jun;48(6):762-9.

Highlights
Three aspects have been relevant and have produced the most important results
in 2013: The research group has established new targets for therapeutic action

based on the modulation of the resections both adipocytokins and transplantation

of liver in marginal organs, which may impact favorably on the quality of life of
patients undergoing resections or transplant and a reduction in liver transplant

waiting lists. The results obtained by the research group have allowed further

participation in competitive programs for the translation of the experimental re-
sults to clinical practice, which will derived in clinical trials and in the creation of a

spin-off. WithregardtotherecurrenceofhepatitisCpost,antiviraltreatmentre-
gimens have been established in candidates for liver transplantation and in those

with severe recurrence of the disease. It has been established the use of invasive

a non-invasive methods to evaluate the severity of hepatitis C recurrence after
transplantation. Finally, patients with operational tolerance to the graft have been

better characterized, doing the elimination of immunosuppressant therapy safer.

Works for development of ex-vivo, normothermic perfusion liver machine are in
progress.

It is important to remark the collaboration established with important groups that

are working in liver disease like Viral Hepatitis Group (Dr. X. Forns) and Portal
Hypertension Group (Dr. J. Bosch).

13
20
T
OR
P
RE
L
A
NU
N
A
D /
H
E
ER
IB
C

109